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Introduction
Radiotherapy continues to be widely used as part of curative treatment for Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Late treatment-related complications have been highlighted, with second malignancy and cardiac toxicity identified as the most common cause of non-lymphoma deaths in HL survivors [1] [2] [3] . Radiotherapy dose to the head and neck region has been shown to increase stroke risk [4] . Multiple studies have demonstrated that complications are related to the irradiated volume [5, 6] .
Modern lymphoma radiotherapy delivery aims to maintain local control rates whilst minimising radiation dose to normal tissues [7] [8] [9] [10] . In 2006 Girinsky et al. [10] PET-CT in the radiotherapy treatment position [11] . The International Lymphoma Radiation Oncology Group (ILROG) developed widely applicable guidelines for involved site radiotherapy (ISRT) [7, 8] . In situations in which radiotherapy is delivered as part of combined modality treatment, the clinical target volume (CTV) is designed to encompass the extent of disease pre-chemotherapy, modified to anatomical boundaries, and expanded to account for any uncertainties in defining the pre-chemotherapy extent of disease, including the quality, position and accuracy of imaging [7, 8] , depending upon clinical judgement [11] . INRT is regarded as ISRT when pre-chemotherapy PET-CT in the radiotherapy treatment position is available [7] .
To date, there has been no data available to directly guide the expansion in CTV to account for the absence of optimal pre-chemotherapy imaging. In this prospective imaging study a series of patients underwent a pre-chemotherapy FDG PET-CT in both standard diagnostic and radiotherapy treatment positions. This study aims to evaluate the magnitude of uncertainty introduced into CTV delineation for nodal neck disease in the absence of a radiotherapy-position pre-chemotherapy PET-CT, in order to quantitatively inform on appropriate CTV expansion.
Methods

Study outline
This is a prospective single centre imaging study in patients with HL or high grade NHL with clinical ± radiological (pre-PET-CT) stage I/II disease potentially suitable for treatment with sequential chemotherapy and radiotherapy (pending PET-CT staging outcome). The imaging protocol incorporates a pre-chemotherapy FDG-PET-CT acquired according to standard diagnostic protocols and, using the same FDG injection, acquisition of an additional FDG-PET-CT scan with intravenous contrast with limited coverage of the head and neck region in the radiotherapy treatment position using radiotherapy mask immobilisation. Treatment was delivered according to institutional clinical protocols.
Patient selection and recruitment
Inclusion criteria were: age ≥18 years old, male or female, histologically proven HL or high A total of 19 patients were recruited between October 2013 and January 2016. All patients provided informed written consent. 12/19 patients subsequently underwent treatment with chemotherapy followed by radiotherapy. 10 of these patients underwent radiotherapy to the neck region and form the basis of this report. 
PET-CT Imaging
Radiotherapy CT planning scan
For patients who were subsequently treated with radiotherapy following chemotherapy the thermoplastic mask fabricated for the pre-chemotherapy PET-CT scan was fitted to assess whether the fit remained optimal. If this was not the case, a new thermoplastic mask was made attempting to maintain a similar neck position. The CT planning scan was acquired with intravenous contrast and 2 or 3mm slice thickness (dependent upon institutional protocols at the time).
CTV contouring
Contouring was performed by radiation oncologists in a single centre specialising in the treatment of lymphoma, with access to clinical history and findings of clinical examination.
When contouring using side-by-side assessment the clinician was blinded to the treatment position PET-CT. To minimise potential for recall, a minimum two week interval was mandated prior to generating contours for each individual patient using different methods.
Contouring using co-registration of PET-CT acquired in radiotherapy position to planning CT scan
Contouring was performed according to the principles of the ILROG guidelines [7, 8] . The contrast-enhanced pre-chemotherapy PET-CT acquired in the radiotherapy position was used to manually contour a gross tumour volume (GTV) based on the morphology of the CT and a GTV based upon the PET images, using predefined window and colour settings (SUV scale 0-7, volcano colour scale for overlayed images). Rigid registration over the whole image was undertaken using Mirada RTx v1.4 software (Mirada Medical, Oxford, UK). All registrations were assessed for clinical suitability by a radiation oncologist. The postchemotherapy CTV (CTVINRT) was contoured, taking into account the co-registered prechemotherapy GTV and changes in lymphoma volume and anatomical position, whilst accounting for anatomical boundaries.
Contouring using side-by-side assessment of PET-CT acquired in diagnostic position
This simulates a situation in which optimal pre-chemotherapy PET-CT imaging in the treatment position is not available (CTVdiagPET). A post-chemotherapy CTV aiming to encompass initially involved lymphoma tissue was contoured using the pre-chemotherapy diagnostic position PET-CT by side-by-side assessment, taking into account changes in lymphoma volume and anatomical changes, whilst accounting for anatomical boundaries.
To allow quantification of the 'errors' introduced by contouring without optimal coregistered imaging, no additional CTV expansion was undertaken.
Data analysis
Assessment of superior and inferior CTV extent
Distance between the superior slices of the CTVINRT and CTVdiagPET was recorded. Distance was similarly recorded for inferior slices.
Positional analysis
Positional metrics were used to compare CTVs in the axial plane. The most superior and inferior overlapping slices of the CTVs (CTVINRT and CTVdiagPET) were defined as the limits of the volume, excluding differences in the superior-inferior CTV length from influencing positional metrics. Positional metrics were also used to assess the intra-observer CTV variability, where all CTV delineations (CTVINRT or CTVdiagPET) were compared to one another. percentage of the volume of CTVINRT. CGD is the distance between the geometric centres of two contours [13] . MDC is the mean of the distances between contours averaged over all positions not within the overlapping contour [13] .
Statistics
All statistical analysis was performed using Matlab2013b (MATLAB and Statistics Toolbox Release 2013b, The MathWorks, Inc., Natick, Massachusetts, United States). Linear mixed effects models were used to determine the significance of the differences between CTVINRT and CTVdiagPET [14] . Significances were determined for the difference in volume and for the following positional metrics: DICE, Se. Idx, CGD and MDC for the CTVINRT and CTVdiagPET axial plane comparison and DICE, Se. Idx, CGD and MDC for the CTVINRT and CTVdiagPET intraobserver comparisons. In all cases, the parameter (volume, DICE, Se. Idx, CGD or MDC) was a fixed effect variable and the patient was a random variable. Data population testing was performed using Q-Q plots to ensure the data was normally distributed. A significant ρ-value was considered to be ρ< 0.05 [15] .
Results
10 patients who entered the study had neck disease and received chemotherapy followed by radiotherapy to the neck region. Baseline characteristics, in addition to prechemotherapy GTV cranio-caudal length and volume are shown in Table 1 . 7 patients had diffuse large B cell lymphoma and 3 had classical HL. All had nodal lymphoma with no extranodal sites. Mean pre-chemotherapy GTV was 64mls. 8/10 received 3 cycles of chemotherapy followed by radiotherapy. 2 patients with DLBCL received 6 cycles of chemotherapy followed by radiotherapy.
Intra-observer variation in CTV generation
Supplementary Table 1 summarises intra-observer variation in delineating CTVINRT and CTVdiagPET based upon delineating 3 consecutive patients 3 times each. Based upon multiple positional metrics, CTVINRT was highly reproducible (mean DICE index 0.88) with minimal variability on the superior and inferior extent of the CTV; metrics for CTVdiagPET showed higher intra-observer variability although reproducibility remained high (mean DICE index 0.80) and variability in the superior and inferior extent of the CTV was very limited.
Supplementary Table 2 
Discussion
FDG PET-CT is a routine staging investigation for lymphoma [16] and identifies sites of disease which need to be included within a CTV which are not identified upon CT imaging [17] . Use of PET-CT is essential to minimise the irradiation volume with ISRT whilst maintaining local control [7, 8, 10] . The concept of ISRT includes an expansion of the CTV to account for uncertainties in imaging including differences in the position in which the prechemotherapy PET-CT is acquired compared with the planning CT [7, 8] ; this expansion is based upon clinical judgement [11] rather than a quantified process. In parallel with the development of the ILROG ISRT guidelines [7, 8] , the UK National Cancer Research Institute Lymphoma Radiotherapy Group [9] developed ISRT guidelines for nodal lymphoma based upon clinical consensus, which specified an additional contoured 1.5cm expansion craniocaudally in the direction of lymphatic spread from the pre-chemotherapy extent of nodal disease with no additional expansion specified in the axial plane.
In this prospective imaging study the acquisition of PET-CT with radiotherapy immobilisation allows generation of INRT CTVs used as a 'gold standard' with which to compare any 'inaccuracy' introduced by contouring using a diagnostic PET-CT used side-by-side with the planning PET-CT. Evaluation of intra-observer variability demonstrated that contouring the CTVINRT using co-registered radiotherapy-position PET-CT is a highly reproducible step (mean DICE 0.88). As expected, this variability was slightly higher for CTVdiagPET, although the positional metrics still showed limited variability in this step (mean DICE 0.80). Similarly, there was minimal variability in determination of the superior and inferior extent of the CTV for both CTVINRT and CTVdiagPET when considered separately. Similar results were obtained when evaluating inter-observer variability, although as would be expected this variation was slightly higher (mean DICE 0.83 for CTVINRT and 0.71 for CTVdiagPET, with superior and inferior variation falling within that for a single observer for all 10 patients). Based upon these findings, subsequent comparisons between CTVINRT and CTVdiagPET are likely to be predominantly accounted for by differences introduced by the use of directly co-registered treatment-position PET-CT or side-by-side evaluation of diagnostic-position PET-CT, rather than intra-observer variability in contouring.
Comparison of the cranio-caudal extent of CTVINRT and CTVdiagPET demonstrated that for the superior and inferior CTV extent, the maximum distance of 'under-contouring' of the CTVdiagPET was 10 and 18mm respectively; mean differences were small (0.4mm superiorly and 3.8mm inferiorly). The patient with 18mm under-contouring at the inferior CTV extent had disease extending into the low neck. The more limited accuracy of defining the inferior CTV extent may relate to the greater variation in position in the lower neck between the pre-chemotherapy PET-CT in the diagnostic position (arms up) and radiotherapy-position.
These data are broadly supportive of the proposal for ISRT of a contoured CTV expansion cranio-caudally of 15mm suggested by the UK guidelines [9] , although based upon these data an expansion of 10mm is sufficient superiorly whilst an expansion of 18mm may be required in the caudal part of the CTV.
Analysis of positional metrics in the axial plane demonstrated that differences between CTVINRT and CTVdiagPET are greater than can be accounted for by intra-observer variation (mean DICE 0.74). The mean Se.Idx of 0.75 suggests that on average only 75% of the CTVINRT was encompassed in the axial plane by the CTVdiagPET. Small differences in CGD show that differences in other positional metrics are not predominantly due to shifts of the whole CTV.
The range of maximum MDC under-coverage was 1.5-14.3mm (mean 7.4). This is despite modification of CTVs to anatomical boundaries. It is noticeable that although superior and inferior CTV expansions are recommended by the UK guidelines [9] , no additional allowance is recommended in the axial plane. These data suggest that a generous approach to contouring ISRT CTVs in the axial plane, within anatomical boundaries, is required in the absence of treatment-position pre-chemotherapy PET-CT.
The data provided by this study provide a general idea of the magnitude of uncertainty in generating CTVs in the neck, and the potential for intra-and inter-observer variation are relevant factors. Although on the sub-analysis intra-and inter-observer variability were limited, it should be noted that the inter-observer analysis is based upon three clinicians at a single centre who are used to reviewing each other's contours. It needs to be considered that there is potential that this variability may be higher between differing centres. It is also critical that clinical judgement should be used when applying these data to individual cases, based upon the anatomical location of the disease in relation to easily identifiable landmarks and the quality/position of pre-chemotherapy imaging. For example, smaller margins may be appropriate when the target volume lies in proximity to easily identifiable anatomical landmarks, whilst larger margins may be appropriate when there is greater clinical uncertainty. In addition, in this study patients were treated with arms down with an immobilisation mask; in other circumstances, eg. involvement of the neck and mediastinum, it is possible to deliver treatment with arms up in a position similar to that adopted for the diagnostic PET-CT which may aid side-by-side comparison with diagnostic imaging but may require a larger margin to the PTV due to greater set up variability. This type of individualised approach to CTV generation reflects that recommended within the ILROG guidelines [7, 8] . It should also be noted that these data cannot be used to guide CTV expansion for ISRT in other anatomical sites eg. mediastinum; easily identifiable anatomical structures within the neck is likely to lead to less uncertainty compared with other sites.
This analysis includes a limited number of patients with variable anatomical distribution and volume of pre-chemotherapy neck disease. Therefore, it is not possible to determine whether there are any differences in the accuracy of CTVdiagPET delineation between patients with large/small volume disease, upper/lower neck disease. There is no clear consensus regarding the optimal method for contouring GTV on PET-CT for multiple tumour types; methods can broadly include visual interpretation or methods of automatic segmentation [18, 19] . It is clear for lymphoma that CT-derived GTV should be included as well as a PETderived GTV [7, 17] . We utilised visual interpretation for this study with strictly controlled image viewing and windowing.
In summary, CTV expansion is required when contouring an ISRT CTV for neck lymphoma when a pre-chemotherapy PET-CT in the radiotherapy treatment position is not available.
Based upon these data, additional CTV expansion cranio-caudally by 10mm superiorly and up to 18mm inferiorly may be necessary, although needs to be individualised depending upon the degree of clinical uncertainty with regard to position and proximity to anatomical landmarks. Contouring should also be generous in the axial plane, whilst respecting anatomical boundaries. represents routine diagnostic pre-chemotherapy PET-CT with arms up, C-F) planning CT scan with CTVINRT (blue)(contoured using co-registered prechemotherapy radiotherapy treatment-position PET-CT) and CTVdiagPET (red) (contoured using side-by-side assessment of diagnostic PET-CT) in the coronal plane (C), in the sagittal plane (D), in the axial plane at the inferior extent of the CTVs (E), in the axial plane at the superior extent of the CTVs (F). 
